Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Exicure Inc (XCUR)

Exicure Inc (XCUR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,328
  • Shares Outstanding, K 87,960
  • Annual Sales, $ 16,610 K
  • Annual Income, $ -24,670 K
  • 60-Month Beta 1.90
  • Price/Sales 9.74
  • Price/Cash Flow N/A
  • Price/Book 2.62
Trade XCUR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -1,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7600 +2.27%
on 04/15/21
2.6797 -32.83%
on 03/18/21
-0.7900 (-30.50%)
since 03/16/21
3-Month
1.7600 +2.27%
on 04/15/21
2.8300 -36.40%
on 02/12/21
-0.5100 (-22.08%)
since 01/15/21
52-Week
1.3800 +30.43%
on 11/23/20
3.3000 -45.45%
on 06/08/20
-0.1500 (-7.69%)
since 04/16/20

Most Recent Stories

More News
Exicure, Inc. (XCUR) Reports Q4 Loss, Misses Revenue Estimates

Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -50.00% and -95.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

XCUR : 1.8000 (-2.17%)
Exicure, Inc. (XCUR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XCUR : 1.8000 (-2.17%)
Exicure Announces Appointment of James Sulat to Board of Directors

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA(TM)) technology, today announced the appointment of James Sulat to its Board...

AMAG : 13.75 (+0.15%)
MNTA : 52.48 (-0.02%)
INRLF : 15.3400 (+3.47%)
XCUR : 1.8000 (-2.17%)
Exicure, Inc. to Present at the virtual Fall Investor Summit on November 16th-18th

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Exicure, Inc. (NYSE American:XCUR), is developing nucleic acid-based therapeutics to treat rare, severe genetic diseases and cancer. XCUR will be presenting...

XCUR : 1.8000 (-2.17%)
Exicure Announces Appointment of Dr. Douglas E. Feltner as Chief Medical Officer

Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA(TM)) constructs, announced today that it has appointed Douglas E. Feltner,...

NVS : 88.02 (+0.94%)
XCUR : 1.8000 (-2.17%)
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board

Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA(TM)) technology, today reported Timothy P. Walbert, Chairman, President and...

XCUR : 1.8000 (-2.17%)
Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

--- Exicure to Host Conference Call Today at 8:30am ET/7:30am CT

XCUR : 1.8000 (-2.17%)
AGN : 193.02 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.

See More

Key Turning Points

3rd Resistance Point 1.9317
2nd Resistance Point 1.8933
1st Resistance Point 1.8467
Last Price 1.8000
1st Support Level 1.7617
2nd Support Level 1.7233
3rd Support Level 1.6767

See More

52-Week High 3.3000
Fibonacci 61.8% 2.5666
Fibonacci 50% 2.3400
Fibonacci 38.2% 2.1134
Last Price 1.8000
52-Week Low 1.3800

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar